Trials / Completed
CompletedNCT05842486
Hematological Response in Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Anti-C5 Antibody: an External Control Arm Study for Iptacopan Use in Anti-C5 naïve Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 92 (actual)
- Sponsor
- Assistance Publique - Hôpitaux de Paris · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this non-interventional secondary use of data study is to evaluate hematological response in patients with paroxysmal nocturnal hemoglobinuria and anemia in the 6-month period after initiation of anti-C5 antibody treatment using real-world data obtained from multiple datasets. The results will be used to contextualize results from the APPOINT-PNH (NCT04820530) trial with iptacopan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Anti-C5 antibody treatment | Anti-C5 antibody treatment (i.e., eculizumab and ravulizumab) |
Timeline
- Start date
- 2023-01-18
- Primary completion
- 2023-03-01
- Completion
- 2023-03-01
- First posted
- 2023-05-06
- Last updated
- 2023-05-06
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05842486. Inclusion in this directory is not an endorsement.